Cholangiocarcinoma and liver transplantation: What we know so far?

Ali Reza Safarpour, Hassan Askari, Farshid Ejtehadi, Asaad Azarnezhad, Ehsan Raeis-Abdollahi, Amir Tajbakhsh, Mohammad Foad Abazari, Firoozeh Tarkesh, Alireza Shamsaeefar, Ramin Niknam, Gholam Reza Sivandzadeh, Kamran Bagheri Lankarani, Fardad Ejtehadi
{"title":"Cholangiocarcinoma and liver transplantation: What we know so far?","authors":"Ali Reza Safarpour,&nbsp;Hassan Askari,&nbsp;Farshid Ejtehadi,&nbsp;Asaad Azarnezhad,&nbsp;Ehsan Raeis-Abdollahi,&nbsp;Amir Tajbakhsh,&nbsp;Mohammad Foad Abazari,&nbsp;Firoozeh Tarkesh,&nbsp;Alireza Shamsaeefar,&nbsp;Ramin Niknam,&nbsp;Gholam Reza Sivandzadeh,&nbsp;Kamran Bagheri Lankarani,&nbsp;Fardad Ejtehadi","doi":"10.4291/wjgp.v12.i5.84","DOIUrl":null,"url":null,"abstract":"<p><p>Cholangiocarcinoma (CCA) is a type of cancer with increasing prevalence around the world that originates from cholangiocytes, the epithelial cells of the bile duct. The tumor begins insidiously and is distinguished by high grade neoplasm, poor outcome, and high risk for recurrence. Liver transplantation has become broadly accepted as a treatment option for CCA. Liver transplantation is expected to play a crucial role as palliative and curative therapy for unresectable hilar CCA and intrahepatic CCA. The purpose of this study was to determine which cases with CCA should be subjected to liver transplantation instead of resection, although reported post-transplant recurrence rate averages approximately 20%. This review also aims to highlight the molecular current frontiers of CCA and directions of liver transplantation for CCA.</p>","PeriodicalId":23760,"journal":{"name":"World Journal of Gastrointestinal Pathophysiology","volume":"12 5","pages":"84-105"},"PeriodicalIF":0.0000,"publicationDate":"2021-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/43/9c/WJGP-12-84.PMC8481789.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Gastrointestinal Pathophysiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4291/wjgp.v12.i5.84","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Cholangiocarcinoma (CCA) is a type of cancer with increasing prevalence around the world that originates from cholangiocytes, the epithelial cells of the bile duct. The tumor begins insidiously and is distinguished by high grade neoplasm, poor outcome, and high risk for recurrence. Liver transplantation has become broadly accepted as a treatment option for CCA. Liver transplantation is expected to play a crucial role as palliative and curative therapy for unresectable hilar CCA and intrahepatic CCA. The purpose of this study was to determine which cases with CCA should be subjected to liver transplantation instead of resection, although reported post-transplant recurrence rate averages approximately 20%. This review also aims to highlight the molecular current frontiers of CCA and directions of liver transplantation for CCA.

Abstract Image

胆管癌和肝移植:到目前为止我们知道什么?
胆管癌(CCA)是一种在世界范围内发病率越来越高的癌症,起源于胆管上皮细胞胆管细胞。肿瘤开始时不明显,特点是高级别肿瘤,预后差,复发风险高。肝移植已被广泛接受为CCA的治疗选择。肝移植有望在不可切除的肝门CCA和肝内CCA的姑息治疗和治愈治疗中发挥关键作用。本研究的目的是确定哪些CCA患者应该接受肝移植而不是切除,尽管报道的移植后复发率平均约为20%。本文综述了CCA的分子研究前沿和CCA肝移植的发展方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信